151.65
+0.65
+(0.43%)
At close: 4:59:39 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
5,716,206
5,716,206
7,062,340
3,150,793
1,897,875
Cost of Revenue
2,897,448
2,897,448
2,459,294
1,449,531
1,327,560
Gross Profit
2,818,758
2,818,758
4,603,046
1,701,262
570,315
Operating Expense
1,878,988
1,878,988
3,100,507
1,772,047
883,862
Operating Income
939,770
939,770
1,502,539
-70,785
-313,547
Net Non Operating Interest Income Expense
-45,272
-45,272
-63,015
-65,273
-118,136
Pretax Income
971,357
971,357
1,482,943
-331,611
-454,430
Tax Provision
-16,620
-16,620
7,754
15,771
10,345
Net Income Common Stockholders
987,977
987,977
1,475,189
-347,382
-464,775
Diluted NI Available to Com Stockholders
987,977
987,977
1,475,189
-347,382
-464,775
Basic EPS
12.60
--
19.20
-4.90
-7.40
Diluted EPS
12.60
--
19.20
-4.90
-7.40
Basic Average Shares
78,103.76
--
76,710.56
70,418.39
63,104
Diluted Average Shares
78,103.76
--
76,710.56
70,418.39
63,104
Total Expenses
4,776,436
4,776,436
5,559,801
3,221,578
2,211,422
Net Income from Continuing & Discontinued Operation
987,977
987,977
1,475,189
-347,382
-464,775
Normalized Income
981,868.82
981,868.82
1,433,500.13
-185,081.94
-434,311.32
Interest Income
48,307
48,307
40,214
26
1,739
Interest Expense
77,872
77,872
105,519
119,689
152,060
Net Interest Income
-45,272
-45,272
-63,015
-65,273
-118,136
EBIT
1,049,229
1,049,229
1,588,462
-211,922
-302,370
EBITDA
1,674,129
1,674,129
2,142,283
187,325
85,940
Reconciled Cost of Revenue
2,897,448
2,897,448
2,459,294
1,449,531
1,327,560
Reconciled Depreciation
624,900
624,900
553,821
399,247
388,310
Net Income from Continuing Operation Net Minority Interest
987,977
987,977
1,475,189
-347,382
-464,775
Total Unusual Items Excluding Goodwill
7,831
7,831
41,908
-208,077
-39,056
Total Unusual Items
7,831
7,831
41,908
-208,077
-39,056
Normalized EBITDA
1,666,298
1,666,298
2,100,375
395,402
124,996
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
1,722.82
1,722.82
219.13
-45,776.94
-8,592.32
12/31/2021 - 1/3/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
GMAB.CO Genmab A/S
1,291.50
-0.12%
ZEAL.CO Zealand Pharma A/S
424.50
-4.61%
GUBRA.CO Gubra A/S
356.00
-4.30%
ALK-B.CO ALK-Abelló A/S
148.60
+1.36%
EXPRS2.ST ExpreS2ion Biotech Holding AB (publ)
19.40
-0.92%
GMAB Genmab A/S
19.55
+0.21%
SANION.ST Saniona AB (publ)
6.15
-6.11%
EVAX Evaxion Biotech A/S
1.3100
-4.38%
PILA.ST Pila Pharma AB (publ)
3.4700
+0.58%
ACE.ST Ascelia Pharma AB (publ)
3.0500
+1.33%